Welcome to
Texas Biologics

Investing in disease prevention and treatment

Learn more about us

Photo credit: NEXU

Akaash Mishra in the lab


Through our innovative programs, Texas Biologics is investing in every phase of biologic development, from research support to clinical evaluation to commercialization.

Learn More

Current Projects

UT researchers are active in the development of new biologic therapies, including enzymes, antibodies, peptides and vaccines.

Learn More

Partner With Us

There are many ways to engage with Texas Biologics, from academic collaboration to technology licensing to philanthropic support.

Learn More

Pilot Grant Awardees

A major goal of Texas Biologics is to strengthen and expand biomedical translational research at UT by providing financial support for projects in biologics discovery and development. We launched the TXBio Pilot Grant Program this year to foster research across campus.

Read more about the 2022 awardees


Patents since 2012


Raised via spinoff companies


Drugs in commercial use or development


January 23, 2023

Jason McLellan, a structural biologist at The University of Texas at Austin, is being honored today with the announcement of two highly prestigious awards—the National Academy of Sciences (NAS) Award in Molecular Biology and the Norman Hackerman Award in Chemical Research from the Welch Foundation.

Read more
October 13, 2022

Nearly two years after COVID-19 vaccines entered widespread use, featuring technology from researchers at The University of Texas at Austin, the Cockrell School of Engineering and the College of Natural Sciences have launched Texas Biologics, a cross-disciplinary effort made up of world-renowned faculty members and researchers working across all areas of therapeutics.

Read more
illustration of antibody attacking metapneumovirus
September 22, 2022

New research could pave the way for a vaccine for a common respiratory virus.

Read more